Risk Factors for Weight Gain Following Switch to Integrase Inhibitor–Based Antiretroviral Therapy
Clicks: 193
ID: 110955
Article Quality & Performance Metrics
Overall Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
0.0
/100
0 views
0 readers
AI Quality Assessment
Not analyzed
We report the first data on within-person weight trajectories following switch to integrase inhibitor-based antiretroviral therapy while virologically suppresse
| Reference Key |
eclinicalrisk
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Lake, Jordan E;for the ACTG A5322 Study Team;Wu, Kunling;for the ACTG A5322 Study Team;Bares, Sara H;for the ACTG A5322 Study Team;Debroy, Paula;for the ACTG A5322 Study Team;Godfrey, Catherine;for the ACTG A5322 Study Team;Koethe, John R;for the ACTG A5322 Study Team;McComsey, Grace A;for the ACTG A5322 Study Team;Palella, Frank J;for the ACTG A5322 Study Team;Tassiopoulos, Katherine;for the ACTG A5322 Study Team;Erlandson, Kristine M;for the ACTG A5322 Study Team; |
| Journal | clinical infectious diseases |
| Year | Year not found |
| DOI | DOI not found |
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.